Another diagnostic for Alzheimers with impact on telehealth gains $2MM funding

Will a market of hundreds of millions be able to access these needed technologies?

Neurotrack, a computer-based cognitive program designed to pick up changes three to six years in advance of an official diagnosis of Alzheimer’s or dementia, gained Series A funding led by Founders’ Fund (Peter Thiel) and joined by Social+Capital Partnership plus several angel investors. Developed initially at Emory University with the technology part of a five year National Institutes of Health (NIH) study, it tests subjects on preference for repeat images versus novel images; a preference for repeat images may indicate a disturbance in the hippocampus area of the brain in completely asymptomatic subjects. However, you will not find it at a doctor’s office or a pharmacy kiosk near you soon. Its initial use will be in clinical trials for pharma companies developing drugs targeting early-stage dementias. The meaning for telehealth and telecare (more…)

An Alzheimer’s diagnosis test that could have profound telecare implications

Significant progress on early diagnosis of Alzheimer’s is reported today by Fierce Diagnostics.  The Cognoptix test involves a laser eye-scanning device and an ophthalmic ointment, according to their website, designed to spot telltale beta-amyloid proteins in the lens of the eye.

The excitement in the article is about the possibility of increasing drug sales; the ability to deploy drugs to delay progression of the disease would clearly be very important. However, whilst perhaps less commercially significant, there would be some huge benefits (more…)